— Albireo subsidiary eligible to receive up to $60 million under agreement — — Decision on Japanese New Drug Application for elobixibat expected in first half of 2018 — BOSTON, Jan. 03, 2018 (GLOBE ...

Progenics could receive $20 million in milestones. Ono Pharmaceutical is paying $15 million for rights to develop Progenics Pharmaceuticals’ opioid-induced constipation drug, Relistor®, in Japan.

Sucampo Pharma, Ltd., a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (SPI) has received approval from the Ministry of Health, Labor and Welfare in Japan for Amitiza (lubiprostone), a ...

(Reuters) - U.S. drugmaker Sucampo Pharmaceuticals is seeking talks with marketing partner Takeda Pharmaceutical Co Ltd to mend their relationship, after losing a two-year legal battle to sever ties ...